• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    2/19/25 6:00:00 AM ET
    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
    Get the next $AEMD alert in real time by email

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 2 - Today

    February 19, 2025

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Light.AI, Inc. (CBOE CA: ALGO) (FSE: 0HC)

    Keynote speaker: Hugh Cleland, Director

    9:40 – 10:10

    Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)

    Keynote speaker: Stephen Anthony Stamp, CEO, CFO & Director

    10:15 – 10:45

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    10:50 – 11:20

    22nd Century Group, Inc. (NASDAQ:XXII)

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    11:25 – 11:55

    Aethlon Medical, Inc. (NASDAQ:AEMD)

    Keynote speakers: Jim Frakes, Acting CEO and CFO & Steven LaRosa, Chief Medical Officer

    12:00 – 12:30

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    12:35 – 1:05

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Dr. David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    1:10 - 1:40

    ANGLE, plc. (OTCQX:ANPCY) (AIM: AGL)

    Keynote speakers: Andrew David William Newland, Founder, CEO & Executive Director

    1:45 - 2:15

    Touchstone Explorations, Inc. (OTC:PBEGF) (TSX:TXP) 

    Keynote speaker: Paul Raymond Baay President, CEO

    2:20 – 2:50

    Mesoblast, Ltd. (NASDAQ:MESO)

    Keynote speakers: Dr. Silviu Itescu, Founder, CEO

    2:55 – 3:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speakers: David Dodd, Chairman, President / CEO

    3:10 - 3:20

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    3:25 - 3:35

    U Power Limited (NASDAQ:UCAR) 

    Keynote speaker: Paul Li, UCAR European Representative

    3:40 – 3:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Thomas Larsen, CEO & Chairman, & Dr. William N. Pearson, Executive Vice President of Exploration

    3:55 – 4:05

    The Birch Co. (OTC:ATWT)

    Keynote speaker: Angus Martin, President & CEO

    4:10 – 4:40

    Sigyn Therapeutics, Inc. (OTCQB:SIGY)

    Keynote speaker: James Allen Joyce, CEO

    _______________________________________________________________

    Day 1

    February 18, 2025

    Companies presented yesterday:

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    B.O.S. Better Online Solutions, Ltd. (NASDAQ:BOSC)

    Keynote speaker: Eyal Cohen, President & CEO

    Brenmiller Energy, Ltd. (NASDAQ:BNRG)

    Keynote speaker: Nir Brenmiller, COO

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    U.S. Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, President, CEO & Director

    Empire Energy (ASX: EEG)

    Keynote speaker: Alex Underwood, CEO & Managing Director

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA) 

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    Highland Copper Company Inc. (OTCQB:HDRSF) (TSXV:HI)

    Keynote speaker: Barry O'Shea, CEO

    Collective Mining, Ltd. (NYSE:CNL) (TSX:CNL)

    Keynote speaker: Ari Sussman, Executive Chairman

    Ideal Power, Inc. (NASDAQ:IPWR)

    Keynote speakers: Dan Brdar, President / CEO, and Tim Burns CFO

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    Beneficient (NASDAQ:BENF)

    Keynote speaker: Brad K. Heppner, CEO

    Jaguar Health, Inc. (NASDAQ:JAGX)

    Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASPI
    $BDRX
    $BENF

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    3/23/2026Overweight → Neutral
    Cantor Fitzgerald
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    More analyst ratings

    $AEMD
    $ASPI
    $BDRX
    $BENF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Somo David M bought $250,000 worth of shares (90,909 units at $2.75), increasing direct ownership by 37% to 338,347 units (SEC Form 4)

    4 - Ideal Power Inc. (0001507957) (Issuer)

    2/26/26 8:49:32 AM ET
    $IPWR
    Semiconductors
    Technology

    CEO Smith Ryan Lewis bought $4,560 worth of shares (4,000 units at $1.14), increasing direct ownership by 0.34% to 1,183,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    9/15/25 7:00:12 AM ET
    $USEG
    Oil & Gas Production
    Energy

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider George Gregory

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/23/26 8:00:19 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Parker Stephen Barry

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/20/26 5:19:51 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Zajac Mark L.

    4 - US ENERGY CORP (0000101594) (Issuer)

    3/20/26 4:33:01 PM ET
    $USEG
    Oil & Gas Production
    Energy

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Brenmiller Energy Issues Business Update Highlighting Commercial Breakthrough, First TES Revenue and BNRG360 Growth Strategy

    Delivered flagship Tempo project, Brenmiller's first commercial-scale boiler replacement deployment, marking a major operational milestone in the Company's transition toward commercializationRecognized first revenue from a TES system sale, validating Brenmiller's ability to convert project execution into reported revenueEntering 2026 with previously disclosed projected 2026 revenue of approximately $1.7 million tied to Tempo execution milestones, which management believes reflects the beginning of an accelerating growth trendLaunched BNRG360 strategy to expand from TES into integrated clean heat-and-power solutions expected to improve project economics, broaden market opportunity and create

    3/25/26 4:10:00 PM ET
    $BNRG
    Building Products
    Industrials

    Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure". The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors

    3/24/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    ASP Isotopes Announces Strategic Collaboration Between Quantum Leap Energy and University of Bristol to Design Advanced Laser Research Facility

    DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that a UK subsidiary of Quantum Leap Energy LLC ("QLE"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has commenced a strategic collaboration with the University of Bristol for the design of a state-of-the-art lithium laser research facility in the UK. This collaboration marks a significant milestone in QLE's commercial strategy to meet rapidly growing market demand for advanced nuclear fuels. Under the terms of the agreement, the University of Bristol will lead the desig

    3/24/26 7:41:43 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral

    3/23/26 8:26:50 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    SEC Filings

    View All

    SEC Form 6-K filed by Brenmiller Energy Ltd

    6-K - Brenmiller Energy Ltd. (0001901215) (Filer)

    3/25/26 4:20:01 PM ET
    $BNRG
    Building Products
    Industrials

    SEC Form 20-F filed by Brenmiller Energy Ltd

    20-F - Brenmiller Energy Ltd. (0001901215) (Filer)

    3/25/26 4:01:24 PM ET
    $BNRG
    Building Products
    Industrials

    Longeveron Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Longeveron Inc. (0001721484) (Filer)

    3/25/26 4:00:38 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Leadership Updates

    Live Leadership Updates

    View All

    Beneficient Appoints Mack H. Hicks to Board of Directors

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced the appointment of Mack H. Hicks as a member of the Company's Board of Directors (the "Board"). Mr. Hicks currently serves as Chief Executive Officer of Hicks Holdings LLC, the Dallas-based family office with operating private equity and real estate investment businesses founded by his late father and private equity pioneer, Thomas O. Hicks, who served as Chairman of the Board of Beneficient until his passing in December of 2025. Mr. Hicks also

    3/12/26 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    - Following PROSERA Phase 3 topline results, the Company is focused on evaluating the totality of the dataset, engaging with the FDA, and assessing strategic options and capital allocation - - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)

    3/17/26 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Gold Mining Scene Continues to Shine Amid Conflict-Driven Price Surge

    VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — As global conflicts continue to grab attention around the world, the price of gold continues to rise[1]. According to analysts at Van Eck the math is strongly favoring gold miners, whose margins and opportunities in the current market's conditions are strengthening[2]. In this environment, companies including GoldHaven Resources (CSE:GOH) (OTCQB:GHVNF), Agnico Eagle Mines (NYSE:AEM) (TSX:AEM), Collective Mining (NYSE:CNL) (TSX:CNL), Kinross Gold (NYSE:KGC) (TSX:K), and New Found Gold (TSXV:NFG) (NYSE-A: NFGC) are advancing high-grade gold projects across multiple jurisdictions as investor dem

    3/12/26 9:05:00 AM ET
    $AEM
    $CNL
    $KGC
    Precious Metals
    Basic Materials